Better Buy in 2026: Pfizer or Merck?
(NYSE: PFE) and (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a somewhat uncertain medium-term outlook as they seek ways to navigate upcoming patent cliffs.
Both could make significant progress toward that goal in 2026, but which one is the better option for investors heading into the new year? Let's find out.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Stock
€23.20
-0.150%
We see a rather positive sentiment for Pfizer Inc. with 14 Buy predictions and 2 Sell predictions.
As a result the target price of 27 € shows a slightly positive potential of 16.38% compared to the current price of 23.2 € for Pfizer Inc..
